ACNE: No
WATER RETENTION: No
HBR: No
HEPATOTOXICITY: No
AROMATIZATION: No
MANUFACTURER: Beligas
WAREHOUSE: International Warehouse 3
SUBSTANCE: GHRH Peptide
Introducing Tesamorelin?a potent growth hormone-releasing factor (GRF) designed to effectively target and reduce excess abdominal fat associated with lipodystrophy in HIV-positive patients.
This innovative treatment is specifically approved for individuals experiencing fat accumulation due to certain HIV therapies, but it is not intended for general weight loss or obesity management.
Use Limitations:
While Tesamorelin holds promise, it is essential to note that long-term cardiovascular safety and benefits are still under investigation. Therefore, continuous evaluation is vital for patients who do not show a significant response, as determined by waist circumference or CT scan results. This product is weight-neutral and does not enhance adherence to antiretroviral therapies.
General Dosing Guidelines:
The recommended dosage for Tesamorelin is 2 mg, administered subcutaneously once daily. For optimal results, inject into the abdomen while rotating sites to avoid areas with scar tissue, bruising, or the navel.
Reconstitution Instructions:
To prepare Tesamorelin, reconstitute using the provided diluent. Combine a 2 mg vial of Tesamorelin with 2.1 mL of diluent by gently rolling the vial in your hands for 30 seconds?avoid vigorous shaking. For detailed guidance, refer to the INSTRUCTIONS FOR USE leaflet included with your product packaging. Administer the solution immediately after reconstitution and dispose of any unused portion. Remember, do not freeze or refrigerate the reconstituted solution.
Administration:
Always inspect the reconstituted Tesamorelin solution for clarity and color before use; it should be clear, colorless, and free of particles. Administer the injection subcutaneously in the abdominal skin, rotating injection sites to ensure even absorption. Avoid injecting into scar tissue, bruises, or the navel.